Mylan Launches Generic Antara® Capsules

                   Mylan Launches Generic Antara® Capsules

PR Newswire

PITTSBURGH, Feb. 25, 2013

PITTSBURGH, Feb. 25, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today
announced that its subsidiary Mylan Pharmaceuticals has begun shipping
Fenofibrate Capsules USP, 43 mg and 130 mg. This product is the generic
version of Lupin Atlantis Holdings, S.A.'s Antara^® Capsules, which are
indicated as an adjunct to diet to reduce elevated LDL-C, Total-C,
triglycerides, and Apo B, and to increase HDL-C in adult patients with primary
hypercholesterolemia or mixed dyslipidemia and to reduce triglyceride levels
in adult patients with severe hypertriglyceridemia. Fenofibrate has not been
shown to reduce coronary heart disease morbidity and mortality in patients
with type 2 diabetes mellitus.

Fenofibrate Capsules USP, 43 mg and 130 mg, had U.S. sales of approximately
$60 million for the 12 months ending Sept. 30, 2012, according to IMS Health.
Mylan has received final approval from the U.S. Food and Drug Administration
(FDA) for its Abbreviated New Drug Application (ANDA) for this product.

Currently, Mylan has 184 ANDAs pending FDA approval representing $80.7 billion
in annual sales, according to IMS Health. Thirty-six of these pending ANDAs
are potential first-to-file opportunities, representing $21.1 billion in
annual brand sales, for the 12 months ending June 30, 2012, according to IMS

Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service a habit, do what's right, not what's easy and impact
the future through passionate global leadership. We offer a growing portfolio
of more than 1,100 generic pharmaceuticals and several brand medications. In
addition, we offer a wide range of antiretroviral therapies, upon which
approximately one-third of HIV/AIDS patients in developing countries depend.
We also operate one of the largest active pharmaceutical ingredient
manufacturers and currently market products in approximately 150 countries and
territories. Our workforce of more than 18,000 people is dedicated to
improving the customer experience and increasing pharmaceutical access to
consumers around the world. But don't take our word for it. See for yourself.
See inside.

SOURCE Mylan Inc.

Contact: Nina Devlin (Media), +1-724-514-1968, or Kris King (Investors),
Press spacebar to pause and continue. Press esc to stop.